{"id":17984,"date":"2011-12-14T00:00:00","date_gmt":"2011-12-14T00:00:00","guid":{"rendered":"https:\/\/cadca1stg.wpengine.com\/resource\/designer-drugs-the-new-frontier\/"},"modified":"2023-10-06T19:27:14","modified_gmt":"2023-10-06T19:27:14","slug":"designer-drugs-new-frontier","status":"publish","type":"resource","link":"https:\/\/www.cadca.org\/fr\/resource\/designer-drugs-new-frontier\/","title":{"rendered":"Drogues de synth\u00e8se\u00a0: la nouvelle fronti\u00e8re"},"content":{"rendered":"<p>Il existe une nouvelle classe de m\u00e9dicaments en constante \u00e9volution et leurs effets ne ressemblent \u00e0 rien de ce que nous avons jamais vu. L&#039;utilisation de drogues de synth\u00e8se telles que les sels de bain et les \u00e9pices augmente rapidement, m\u00eame si des lois et des ordonnances entrent en vigueur pour aider \u00e0 contr\u00f4ler leur propagation.<\/p>\n<p>Au cours de ce programme d&#039;une heure, <em><strong>Drogues de synth\u00e8se\u00a0: la nouvelle fronti\u00e8re<\/strong><\/em>, nous examinerons cette menace nouvelle et \u00e9mergente li\u00e9e aux drogues, d\u00e9couvrirons qui est le plus \u00e0 risque et apprendrons ce que nous pouvons faire \u00e0 ce sujet. Nous nous rendrons \u00e0 Bangor, dans le Maine, o\u00f9 certains experts disent qu&#039;il s&#039;agit de la pire \u00e9pid\u00e9mie de drogue qu&#039;ils aient jamais vue. L&#039;\u00e9mission est diffus\u00e9e <strong>26 janvier 2012 \u00e0 13 h HNE.<\/strong><\/p>\n<p><strong>Concepts cl\u00e9s:<\/strong><\/p>\n<ul>\n<li>Quelles sont ces drogues de synth\u00e8se\u00a0?<\/li>\n<li>Que peut-il arriver aux personnes qui les prennent ?<\/li>\n<li>Quelles strat\u00e9gies les coalitions peuvent-elles utiliser pour emp\u00eacher leur utilisation ?<\/li>\n<li>Que doivent savoir les forces de l&#039;ordre lorsqu&#039;elles approchent une personne susceptible de consommer des drogues de synth\u00e8se\u00a0?<\/li>\n<\/ul>\n<p><strong>H\u00e9berg\u00e9 par:<\/strong><\/p>\n<p><strong>Mary Elizabeth Elliott,<\/strong> <em>Vice-pr\u00e9sident des communications, des adh\u00e9sions et des technologies de l&#039;information, CADCA<\/em><\/p>\n<p><strong>Fournisseurs de contenu:<\/strong><\/p>\n<p><strong>Gary Bogg<\/strong>, <em>Agent sp\u00e9cial, assistant ex\u00e9cutif, Office of Diversion Control, US Drug Enforcement Administration<\/em><\/p>\n<p>Gary Boggs a commenc\u00e9 sa carri\u00e8re dans l&#039;application de la loi au d\u00e9partement du sh\u00e9rif du comt\u00e9 d&#039;Orange \u00e0 Orlando, en Floride, en 1977, o\u00f9 il a \u00e9t\u00e9 affect\u00e9 \u00e0 la division de patrouille et \u00e0 la Street Drug Unit.<\/p>\n<p>En 1985, il est devenu agent sp\u00e9cial aupr\u00e8s de la Drug Enforcement Administration des \u00c9tats-Unis et a \u00e9t\u00e9 transf\u00e9r\u00e9 au Detroit Field Division Office. En 2003, il a \u00e9t\u00e9 transf\u00e9r\u00e9 au si\u00e8ge de la DEA, o\u00f9 il a \u00e9t\u00e9 affect\u00e9 au Bureau du renseignement sp\u00e9cial en tant que chef d&#039;unit\u00e9 sur les programmes classifi\u00e9s.<\/p>\n<p>En 2006, Boggs a \u00e9t\u00e9 promu \u00e0 son poste actuel d&#039;adjoint ex\u00e9cutif de l&#039;administrateur adjoint adjoint du Bureau du contr\u00f4le des d\u00e9tournements. En tant qu&#039;adjoint ex\u00e9cutif, il coordonne les op\u00e9rations quotidiennes du Programme de contr\u00f4le des d\u00e9tournements; \u00e9labore des propositions de politique et de budget\u00a0; fournit des s\u00e9ances d&#039;information aux membres du Congr\u00e8s\u00a0; et assure la liaison avec l&#039;industrie.<\/p>\n<p>L&#039;agent sp\u00e9cial Boggs est titulaire d&#039;un baccalaur\u00e9at \u00e8s sciences en justice p\u00e9nale de la Georgia Southern University.<\/p>\n<p><strong>Aaron Byzak<\/strong>, <em>Pr\u00e9sident, North Coastal Prevention Coalition (NCPC), Vista, Californie<\/em><\/p>\n<p>Aaron Byzak est pr\u00e9sident de la North Coastal Prevention Coalition (NCPC) depuis 2008 et si\u00e8ge \u00e0 son conseil d&#039;administration depuis 2003. En 2010, la NCPC a \u00e9t\u00e9 reconnue par la National Association of State Alcohol &amp; Drug Abuse Directors (NASADAD) avec le 2010 Prix national exemplaire pour les programmes, pratiques et politiques novateurs de pr\u00e9vention de l&#039;abus de substances.<\/p>\n<p>Byzak est le directeur des affaires gouvernementales et communautaires pour les sciences de la sant\u00e9 de l&#039;UC San Diego. Dans ce r\u00f4le, Aaron g\u00e8re toutes les activit\u00e9s de relations l\u00e9gislatives et communautaires au nom du syst\u00e8me de sant\u00e9 de l&#039;UC San Diego, de la facult\u00e9 de m\u00e9decine de l&#039;UCSD et de la facult\u00e9 de pharmacie et des sciences pharmaceutiques de Skaggs \u00e0 l&#039;UCSD.<\/p>\n<p>Byzak est titulaire d&#039;un BA en sciences sociales de l&#039;Universit\u00e9 Chapman et d&#039;un MBA en gestion et politique des soins de sant\u00e9 de la Paul Merage School of Business de l&#039;Universit\u00e9 de Californie \u00e0 Irvine. Il est actuellement inscrit au programme de certificat en leadership ex\u00e9cutif de l&#039;Universit\u00e9 Cornell.<\/p>\n<p><strong>Marc Ryan<\/strong><em>, Pharm.D., Directeur, Louisiana Poison Center<\/em><\/p>\n<p>Le Dr Mark Ryan est le directeur du Louisiana Poison Center, o\u00f9 il aide \u00e0 la prise en charge m\u00e9dicale des patients empoisonn\u00e9s ou en surdose et dispense des cours de pr\u00e9vention et de sensibilisation aux empoisonnements pour aider \u00e0 r\u00e9duire l&#039;incidence des empoisonnements accidentels.<\/p>\n<p>R\u00e9sident permanent de la Louisiane, le Dr Ryan est dipl\u00f4m\u00e9 de la Northeast Louisiana University avec un baccalaur\u00e9at \u00e8s sciences en aviation. &quot;J&#039;adore piloter des avions mais aider les autres est ma passion&quot;. Le Dr Ryan a obtenu son dipl\u00f4me de premier cycle en pharmacie de l&#039;Universit\u00e9 de Louisiane \u00e0 Monroe et a obtenu son doctorat en pharmacie de l&#039;Universit\u00e9 du Kansas.<\/p>\n<p>Il est professeur adjoint de m\u00e9decine d&#039;urgence clinique au LSU Health Sciences Center \u00e0 Shreveport, ce qui lui donne l&#039;occasion d&#039;enseigner aux \u00e9tudiants en m\u00e9decine, aux r\u00e9sidents, aux boursiers et \u00e0 d&#039;autres professionnels de la sant\u00e9 la toxicologie clinique.<br \/>\nSes domaines d&#039;int\u00e9r\u00eat comprennent les morsures d&#039;araign\u00e9es et de serpents, les drogues de synth\u00e8se, la toxicit\u00e9 de l&#039;ac\u00e9taminoph\u00e8ne, les interventions d&#039;urgence, les op\u00e9rations pharmaceutiques dans les refuges pour \u00e9vacu\u00e9s et les agents d&#039;opportunit\u00e9.<\/p>","protected":false},"excerpt":{"rendered":"<p>There\u2019s a new and ever-changing class of drugs out there and their effects are unlike anything we have ever seen.<\/p>","protected":false},"author":23,"featured_media":4018,"template":"","resource_type":[350],"drug_specific_issues":[],"action_to_do":[],"class_list":["post-17984","resource","type-resource","status-publish","has-post-thumbnail","hentry","resource_type-video"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Designer Drugs: The New Frontier | CADCA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cadca.org\/fr\/resource\/designer-drugs-new-frontier\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Designer Drugs: The New Frontier | CADCA\" \/>\n<meta property=\"og:description\" content=\"There\u2019s a new and ever-changing class of drugs out there and their effects are unlike anything we have ever seen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cadca.org\/fr\/resource\/designer-drugs-new-frontier\/\" \/>\n<meta property=\"og:site_name\" content=\"CADCA\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-06T19:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"258\" \/>\n\t<meta property=\"og:image:height\" content=\"172\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/\",\"url\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/\",\"name\":\"Designer Drugs: The New Frontier | CADCA\",\"isPartOf\":{\"@id\":\"https:\/\/www.cadca.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg\",\"datePublished\":\"2011-12-14T00:00:00+00:00\",\"dateModified\":\"2023-10-06T19:27:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#primaryimage\",\"url\":\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg\",\"contentUrl\":\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg\",\"width\":258,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cadca.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Designer Drugs: The New Frontier\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cadca.org\/#website\",\"url\":\"https:\/\/www.cadca.org\/\",\"name\":\"CADCA\",\"description\":\"The Premier Prevention Association\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cadca.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Designer Drugs: The New Frontier | CADCA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cadca.org\/fr\/resource\/designer-drugs-new-frontier\/","og_locale":"fr_FR","og_type":"article","og_title":"Designer Drugs: The New Frontier | CADCA","og_description":"There\u2019s a new and ever-changing class of drugs out there and their effects are unlike anything we have ever seen.","og_url":"https:\/\/www.cadca.org\/fr\/resource\/designer-drugs-new-frontier\/","og_site_name":"CADCA","article_modified_time":"2023-10-06T19:27:14+00:00","og_image":[{"width":258,"height":172,"url":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/","url":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/","name":"Designer Drugs: The New Frontier | CADCA","isPartOf":{"@id":"https:\/\/www.cadca.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#primaryimage"},"image":{"@id":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg","datePublished":"2011-12-14T00:00:00+00:00","dateModified":"2023-10-06T19:27:14+00:00","breadcrumb":{"@id":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#primaryimage","url":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg","contentUrl":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/designerdrugs.jpg","width":258,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cadca.org\/resource\/designer-drugs-new-frontier\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cadca.org\/"},{"@type":"ListItem","position":2,"name":"Designer Drugs: The New Frontier"}]},{"@type":"WebSite","@id":"https:\/\/www.cadca.org\/#website","url":"https:\/\/www.cadca.org\/","name":"CADCA","description":"The Premier Prevention Association","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cadca.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource\/17984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/users\/23"}],"version-history":[{"count":0,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource\/17984\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/media\/4018"}],"wp:attachment":[{"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/media?parent=17984"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/resource_type?post=17984"},{"taxonomy":"drug_specific_issues","embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/drug_specific_issues?post=17984"},{"taxonomy":"action_to_do","embeddable":true,"href":"https:\/\/www.cadca.org\/fr\/wp-json\/wp\/v2\/action_to_do?post=17984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}